Literature DB >> 19246449

FOXO1 transrepresses peroxisome proliferator-activated receptor gamma transactivation, coordinating an insulin-induced feed-forward response in adipocytes.

Wuqiang Fan1, Takeshi Imamura, Noriyuki Sonoda, Dorothy D Sears, David Patsouris, Jane J Kim, Jerrold M Olefsky.   

Abstract

The transcriptional factor FoxO1 plays an important role in metabolic homeostasis. Herein we identify a novel transrepressional function that converts FoxO1 from an activator of transcription to a promoter-specific repressor of peroxisome proliferator-activated receptor gamma (PPARgamma) target genes that regulate adipocyte biology. FoxO1 transrepresses PPARgamma via direct protein-protein interactions; it is recruited to PPAR response elements (PPRE) on PPARgamma target genes by PPARgamma bound to PPRE and interferes with promoter DNA occupancy of the receptor. The FoxO1 transrepressional function, which is independent and dissectible from the transactivational effects, does not require a functional FoxO1 DNA binding domain, but dose require an evolutionally conserved 31 amino acids LXXLL-containing domain. Insulin induces FoxO1 phosphorylation and nuclear exportation, which prevents FoxO1-PPARgamma interactions and rescues transrepression. Adipocytes from insulin resistant mice show reduced phosphorylation and increased nuclear accumulation of FoxO1, which is coupled to lowered expression of endogenous PPARgamma target genes. Thus the innate FoxO1 transrepression function enables insulin to augment PPARgamma activity, which in turn leads to insulin sensitization, and this feed-forward cycle represents positive reinforcing connections between insulin and PPARgamma signaling.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19246449      PMCID: PMC2673287          DOI: 10.1074/jbc.M808915200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro.

Authors:  E D Rosen; P Sarraf; A E Troy; G Bradwin; K Moore; D S Milstone; B M Spiegelman; R M Mortensen
Journal:  Mol Cell       Date:  1999-10       Impact factor: 17.970

2.  Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma.

Authors:  Serena Ghisletti; Wendy Huang; Sumito Ogawa; Gabriel Pascual; Mu-En Lin; Timothy M Willson; Michael G Rosenfeld; Christopher K Glass
Journal:  Mol Cell       Date:  2007-01-12       Impact factor: 17.970

3.  An SH2 domain-containing 5' inositolphosphatase inhibits insulin-induced GLUT4 translocation and growth factor-induced actin filament rearrangement.

Authors:  P Vollenweider; M Clodi; S S Martin; T Imamura; W M Kavanaugh; J M Olefsky
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

4.  Nuclear compartmentalization of N-CoR and its interactions with steroid receptors.

Authors:  Yin Wu; Hisaya Kawate; Keizo Ohnaka; Hajime Nawata; Ryoichi Takayanagi
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

5.  The LXXLL motif of murine forkhead transcription factor FoxO1 mediates Sirt1-dependent transcriptional activity.

Authors:  Jun Nakae; Yongheng Cao; Hiroaki Daitoku; Akiyoshi Fukamizu; Wataru Ogawa; Yoshihiko Yano; Yoshitake Hayashi
Journal:  J Clin Invest       Date:  2006-08-17       Impact factor: 14.808

6.  Androgen receptor null male mice develop late-onset obesity caused by decreased energy expenditure and lipolytic activity but show normal insulin sensitivity with high adiponectin secretion.

Authors:  WuQiang Fan; Toshihiko Yanase; Masatoshi Nomura; Taijiro Okabe; Kiminobu Goto; Takashi Sato; Hirotaka Kawano; Shigeaki Kato; Hajime Nawata
Journal:  Diabetes       Date:  2005-04       Impact factor: 9.461

7.  Aberrant Forkhead box O1 function is associated with impaired hepatic metabolism.

Authors:  Shen Qu; Jennifer Altomonte; German Perdomo; Jing He; Yong Fan; Adama Kamagate; Marcia Meseck; H Henry Dong
Journal:  Endocrinology       Date:  2006-09-21       Impact factor: 4.736

8.  Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

Authors:  Victor Lawrence Roberts; John Stewart; Maher Issa; Barbara Lake; Robert Melis
Journal:  Clin Ther       Date:  2005-10       Impact factor: 3.393

9.  FOXO1 represses peroxisome proliferator-activated receptor-gamma1 and -gamma2 gene promoters in primary adipocytes. A novel paradigm to increase insulin sensitivity.

Authors:  Michal Armoni; Chava Harel; Shiri Karni; Hui Chen; Fabiana Bar-Yoseph; Marel R Ver; Michael J Quon; Eddy Karnieli
Journal:  J Biol Chem       Date:  2006-05-02       Impact factor: 5.157

10.  Dok1 mediates high-fat diet-induced adipocyte hypertrophy and obesity through modulation of PPAR-gamma phosphorylation.

Authors:  Tetsuya Hosooka; Tetsuya Noguchi; Ko Kotani; Takehiro Nakamura; Hiroshi Sakaue; Hiroshi Inoue; Wataru Ogawa; Kazutoshi Tobimatsu; Kazuo Takazawa; Mashito Sakai; Yasushi Matsuki; Ryuji Hiramatsu; Tomoharu Yasuda; Mitchell A Lazar; Yuji Yamanashi; Masato Kasuga
Journal:  Nat Med       Date:  2008-01-20       Impact factor: 53.440

View more
  50 in total

1.  Putting the brakes on FOXO1 in fat.

Authors:  Jane J Kim; Wuqiang Fan; Jerrold M Olefsky
Journal:  EMBO J       Date:  2012-04-17       Impact factor: 11.598

2.  FoxO1 regulates Tlr4 inflammatory pathway signalling in macrophages.

Authors:  Wuqiang Fan; Hidetaka Morinaga; Jane J Kim; Eunju Bae; Nathanael J Spann; Sven Heinz; Christopher K Glass; Jerrold M Olefsky
Journal:  EMBO J       Date:  2010-11-02       Impact factor: 11.598

3.  FoxO1-autophagy axis regulates lipid droplet growth via FSP27.

Authors:  Sukanta Jash; Vishwajeet Puri
Journal:  Cell Cycle       Date:  2016-08-12       Impact factor: 4.534

4.  Isotretinoin and FoxO1: A scientific hypothesis.

Authors:  Bodo C Melnik
Journal:  Dermatoendocrinol       Date:  2011-07-01

Review 5.  Targeting Forkhead box O1 from the concept to metabolic diseases: lessons from mouse models.

Authors:  Zhiyong Cheng; Morris F White
Journal:  Antioxid Redox Signal       Date:  2010-09-16       Impact factor: 8.401

6.  Adipocyte iron regulates adiponectin and insulin sensitivity.

Authors:  J Scott Gabrielsen; Yan Gao; Judith A Simcox; Jingyu Huang; David Thorup; Deborah Jones; Robert C Cooksey; David Gabrielsen; Ted D Adams; Steven C Hunt; Paul N Hopkins; William T Cefalu; Donald A McClain
Journal:  J Clin Invest       Date:  2012-09-10       Impact factor: 14.808

7.  Up-regulation of adiponectin by resveratrol: the essential roles of the Akt/FOXO1 and AMP-activated protein kinase signaling pathways and DsbA-L.

Authors:  Anping Wang; Meilian Liu; Xianling Liu; Lily Q Dong; Randolph D Glickman; Thomas J Slaga; Zhiguang Zhou; Feng Liu
Journal:  J Biol Chem       Date:  2010-10-27       Impact factor: 5.157

Review 8.  Adiponectin, driver or passenger on the road to insulin sensitivity?

Authors:  Risheng Ye; Philipp E Scherer
Journal:  Mol Metab       Date:  2013-04-19       Impact factor: 7.422

9.  Insulin acts through FOXO3a to activate transcription of plasminogen activator inhibitor type 1.

Authors:  Ushma R Jag; Jiri Zavadil; Frederick M Stanley
Journal:  Mol Endocrinol       Date:  2009-07-16

10.  Insulin Is Required to Maintain Albumin Expression by Inhibiting Forkhead Box O1 Protein.

Authors:  Qing Chen; Mingjian Lu; Bobby R Monks; Morris J Birnbaum
Journal:  J Biol Chem       Date:  2015-12-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.